Preface |
|
xix | |
I Immunology |
|
1 | (232) |
|
|
3 | (7) |
|
|
3 | (3) |
|
|
4 | (1) |
|
|
4 | (2) |
|
The Inflammatory Response |
|
|
6 | (2) |
|
Immunopathology (the Double-Edged Sword) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
9 | (1) |
|
Cells of the Immune System |
|
|
10 | (23) |
|
The Blood and Lymphoid Systems |
|
|
10 | (1) |
|
|
10 | (14) |
|
|
10 | (1) |
|
|
11 | (13) |
|
Cellular Interactions in Immune Responses |
|
|
24 | (1) |
|
Hematopoiesis (Blood Formation) |
|
|
25 | (5) |
|
|
27 | (1) |
|
Hematopoietic Factor Treatment of Human Diseases |
|
|
27 | (3) |
|
|
30 | (1) |
|
|
30 | (3) |
|
Inflammation and Wound Healing |
|
|
33 | (68) |
|
|
33 | (2) |
|
|
35 | (3) |
|
Initiation of Inflammation |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
|
36 | (2) |
|
Classification of Inflammation |
|
|
38 | (1) |
|
The Cells of Acute Inflammation |
|
|
38 | (16) |
|
|
38 | (1) |
|
|
38 | (1) |
|
|
39 | (1) |
|
|
40 | (4) |
|
|
44 | (1) |
|
Polymorphonuclear Neutrophils |
|
|
45 | (2) |
|
|
47 | (6) |
|
|
53 | (1) |
|
|
54 | (15) |
|
|
54 | (9) |
|
|
63 | (3) |
|
|
66 | (1) |
|
|
66 | (3) |
|
Adult Respiratory Distress Syndrome |
|
|
69 | (1) |
|
Interrelationships of Inflammatory Cells and Protein Systems in Acute Inflammation |
|
|
69 | (2) |
|
|
71 | (1) |
|
The Cells of Chronic Inflammation |
|
|
71 | (6) |
|
|
71 | (1) |
|
|
72 | (5) |
|
Cytokines in Chronic Inflammation |
|
|
77 | (3) |
|
|
77 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
79 | (1) |
|
|
79 | (1) |
|
|
80 | (1) |
|
|
80 | (3) |
|
|
83 | (2) |
|
|
83 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
85 | (3) |
|
|
85 | (2) |
|
|
87 | (1) |
|
Review of Mediators of Inflammation |
|
|
88 | (1) |
|
Manifestations of Inflammation in Tissues |
|
|
89 | (1) |
|
Cytokines, Adhesion Molecules, and Growth Factors in Atherosclerosis |
|
|
90 | (1) |
|
|
91 | (4) |
|
|
92 | (1) |
|
|
92 | (3) |
|
|
95 | (1) |
|
|
96 | (1) |
|
|
96 | (5) |
|
|
101 | (49) |
|
|
101 | (1) |
|
|
101 | (4) |
|
|
103 | (1) |
|
|
104 | (1) |
|
|
105 | (12) |
|
|
105 | (1) |
|
|
105 | (2) |
|
Variable and Constant Domains |
|
|
107 | (1) |
|
|
108 | (1) |
|
|
109 | (2) |
|
Human Heavy-Chain Isotypes |
|
|
111 | (3) |
|
|
114 | (1) |
|
Diversity of Antibody Specificity |
|
|
114 | (2) |
|
Antigenic Determinants (Epitopes) |
|
|
116 | (1) |
|
|
116 | (1) |
|
|
117 | (1) |
|
Antibody-Antigen Reactions |
|
|
117 | (12) |
|
|
117 | (1) |
|
|
118 | (2) |
|
|
120 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
122 | (1) |
|
|
122 | (4) |
|
Antibody Affinity Chromatography |
|
|
126 | (1) |
|
|
127 | (1) |
|
Antigen-Antibody Reaction In Vivo |
|
|
128 | (1) |
|
The B-Cell Receptor (BCR) |
|
|
129 | (2) |
|
The BCR as a Signal Transducer |
|
|
129 | (1) |
|
The BCR in Antigen Presentation |
|
|
130 | (1) |
|
|
131 | (11) |
|
|
131 | (1) |
|
Light-Chain V Gene Assembly |
|
|
131 | (4) |
|
|
135 | (7) |
|
|
142 | (2) |
|
|
142 | (1) |
|
CD Markers of B-Cell Differentiation |
|
|
142 | (1) |
|
|
142 | (2) |
|
Gene Rearrangements in Lymphomas and Leukemias |
|
|
144 | (1) |
|
Application of Antibody Technology to Therapy |
|
|
145 | (2) |
|
|
147 | (1) |
|
|
147 | (3) |
|
All about T Cells and Induction of Immunity |
|
|
150 | (48) |
|
T Cells and the Immune Response |
|
|
150 | (6) |
|
T-Cell Recognition of Antigens |
|
|
150 | (1) |
|
Clonal Expansion of T Cells |
|
|
151 | (2) |
|
|
153 | (1) |
|
|
153 | (1) |
|
|
153 | (3) |
|
|
156 | (3) |
|
|
156 | (2) |
|
|
158 | (1) |
|
|
158 | (1) |
|
|
159 | (11) |
|
|
159 | (1) |
|
|
159 | (3) |
|
|
162 | (1) |
|
|
162 | (1) |
|
|
163 | (1) |
|
|
163 | (1) |
|
|
164 | (1) |
|
|
164 | (1) |
|
Antigen Processing and Presentation |
|
|
164 | (1) |
|
Endosomal or Exogenous Processing |
|
|
165 | (1) |
|
Nonendosomal or Endogenous Processing |
|
|
165 | (3) |
|
|
168 | (2) |
|
The Major Histocompatibility Complex |
|
|
170 | (4) |
|
|
171 | (1) |
|
|
171 | (1) |
|
|
171 | (2) |
|
|
173 | (1) |
|
T-Cell-B-Cell Interactions, the MHC, and the Immune Response |
|
|
174 | (6) |
|
MHC Recognition by T Cells |
|
|
175 | (1) |
|
|
176 | (2) |
|
T-Cell Populations and Control of the Immune Response |
|
|
178 | (2) |
|
Prophylactic Immunization (Vaccination) |
|
|
180 | (11) |
|
|
180 | (2) |
|
Vaccination for Antibody Production |
|
|
182 | (1) |
|
Vaccine Design: Influenza Virus |
|
|
183 | (2) |
|
Vaccine Potency: Haemophilus influenzae |
|
|
185 | (1) |
|
Control of the Type of Immune Response |
|
|
186 | (5) |
|
|
191 | (2) |
|
|
193 | (5) |
|
|
198 | (35) |
|
The Lymphatic System: Vessels and Organs |
|
|
198 | (3) |
|
|
198 | (3) |
|
Lymphoid Organs: Structure and Function |
|
|
201 | (24) |
|
|
201 | (6) |
|
Peripheral Lymphoid Organs |
|
|
207 | (9) |
|
Innervation of Lymphoid Organs |
|
|
216 | (1) |
|
Comparison of the Structures of Lymphoid Organs |
|
|
217 | (1) |
|
|
217 | (2) |
|
The Effect of Antigens on Lymphoid Tissue |
|
|
219 | (5) |
|
|
224 | (1) |
|
Activated Lymphoid Traffic |
|
|
224 | (1) |
|
Development of Lymphoid Organs (Ontogeny) |
|
|
225 | (2) |
|
|
225 | (2) |
|
|
227 | (1) |
|
|
227 | (6) |
II Immunopathology and Immunity |
|
233 | (452) |
|
|
235 | (5) |
|
Immunity, Immunopathology, Hypersensitivity, and Allergy |
|
|
235 | (1) |
|
Immune Effector Mechanisms |
|
|
236 | (2) |
|
Antibody-Directed Immune Effector Mechanisms |
|
|
236 | (1) |
|
Cell-Mediated Immune Effector Mechanisms |
|
|
237 | (1) |
|
The ``Double-Edged Sword'' of Immune Defense Mechanisms |
|
|
238 | (1) |
|
|
239 | (1) |
|
Inactivation and Activation of Biologically Active Molecules |
|
|
240 | (36) |
|
Mechanisms of Antibody-Mediated Inactivation and Activation |
|
|
240 | (4) |
|
|
240 | (3) |
|
|
243 | (1) |
|
Examples of Antibody-Mediated Inactivation and Activation |
|
|
244 | (16) |
|
|
244 | (5) |
|
|
249 | (9) |
|
Other Biologically Active Molecules |
|
|
258 | (1) |
|
|
259 | (1) |
|
Ligands, Receptors, and Idiotypes |
|
|
260 | (1) |
|
Anti-Idiotypes and Ligand Mimicry |
|
|
260 | (1) |
|
Anti-Idiotypes and Disease |
|
|
260 | (1) |
|
Neutralizing Antibodies: Cause and Effect |
|
|
261 | (1) |
|
Protective Functions of Inactivating (Neutralizing) Antibodies |
|
|
262 | (8) |
|
|
263 | (2) |
|
|
265 | (1) |
|
|
266 | (4) |
|
|
270 | (1) |
|
|
270 | (6) |
|
Cytotoxic and Cytolytic Reactions |
|
|
276 | (26) |
|
The Mechanism of Cytolytic Reactions |
|
|
276 | (2) |
|
Immunohematologic Diseases |
|
|
278 | (13) |
|
|
278 | (10) |
|
Leukocytes (Agranulocytosis) |
|
|
288 | (1) |
|
|
289 | (1) |
|
Immune Suppression of Blood Cell Production |
|
|
290 | (1) |
|
|
291 | (1) |
|
Other Cytotoxic Reactions |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
292 | (1) |
|
|
292 | (1) |
|
Detection of Circulating Cytotoxic Antibodies |
|
|
292 | (1) |
|
Passive Transfer (In Vivo) |
|
|
292 | (1) |
|
|
292 | (1) |
|
Protective and Pathologic Effects in Infectious Diseases |
|
|
293 | (6) |
|
|
293 | (6) |
|
|
299 | (1) |
|
|
299 | (3) |
|
|
302 | (57) |
|
|
302 | (1) |
|
|
302 | (2) |
|
|
304 | (3) |
|
Immune Complexes in Infectious Diseases |
|
|
307 | (1) |
|
|
308 | (10) |
|
|
308 | (4) |
|
Chronic Glomerulonephritis |
|
|
312 | (1) |
|
Anti-Glomerular Basement Nephritis |
|
|
313 | (1) |
|
|
314 | (2) |
|
|
316 | (1) |
|
Clinical-Immunopathologic Correlations in Glomerulonephritis |
|
|
317 | (1) |
|
Human Glomerular Diseases |
|
|
318 | (1) |
|
|
318 | (5) |
|
|
320 | (1) |
|
Kawasaki Syndrome (Mucocutaneous Lymph Node Syndrome) |
|
|
320 | (2) |
|
Hypocomplementemic Vasculitic Urticarial Syndrome |
|
|
322 | (1) |
|
|
322 | (1) |
|
Post-Cardiac Bypass Syndrome |
|
|
322 | (1) |
|
|
322 | (1) |
|
|
322 | (1) |
|
Cutaneous Vasculitis in Infectious Diseases |
|
|
322 | (1) |
|
|
323 | (2) |
|
Diffuse Connective Tissue Diseases |
|
|
325 | (27) |
|
|
327 | (1) |
|
|
328 | (6) |
|
Spondyloarthropathies and HLA-B27 |
|
|
334 | (1) |
|
Systemic Lupus Erythematosus (SLE) |
|
|
335 | (9) |
|
Sjogren's Syndrome (Sicca Complex) |
|
|
344 | (2) |
|
Inflammatory Myopathies (Dermatomyositis and Polymyositis) |
|
|
346 | (2) |
|
Progressive Systemic Sclerosis (PSS, or Scleroderma) |
|
|
348 | (2) |
|
Mixed Connective Tissue Disease and Overlap Syndromes |
|
|
350 | (1) |
|
Thrombotic Microangiopathies |
|
|
351 | (1) |
|
|
351 | (1) |
|
Other Immune Complex Diseases |
|
|
352 | (1) |
|
Cellular Interstitial Pneumonia |
|
|
352 | (1) |
|
|
352 | (1) |
|
Choroid Plexus Deposition |
|
|
352 | (1) |
|
|
352 | (1) |
|
Evaluation of Circulating Immune Complexes |
|
|
353 | (1) |
|
|
353 | (1) |
|
|
353 | (6) |
|
Atopic and Anaphylactic Reactions (Allergy) |
|
|
359 | (42) |
|
|
359 | (3) |
|
|
359 | (1) |
|
|
360 | (1) |
|
Comparison of Anaphylactic and Atopic Reactions |
|
|
361 | (1) |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
362 | (1) |
|
Natural Distribution of Allergens |
|
|
363 | (1) |
|
|
363 | (4) |
|
|
364 | (1) |
|
|
364 | (1) |
|
Clinical Antibody Tests (In Vivo) |
|
|
365 | (1) |
|
Laboratory Tests (In Vitro) |
|
|
366 | (1) |
|
Mediator Release from Mast Cells |
|
|
367 | (1) |
|
|
367 | (2) |
|
|
367 | (1) |
|
|
367 | (2) |
|
|
369 | (1) |
|
|
369 | (1) |
|
Route of Access of Antigen |
|
|
369 | (1) |
|
|
369 | (1) |
|
|
369 | (1) |
|
Familial Susceptibility (Genetics) |
|
|
370 | (1) |
|
|
370 | (5) |
|
|
371 | (1) |
|
|
372 | (1) |
|
|
372 | (1) |
|
|
372 | (2) |
|
|
374 | (1) |
|
|
375 | (5) |
|
Hay Fever (Seasonal Allergic Rhinitis) |
|
|
375 | (1) |
|
|
376 | (1) |
|
|
377 | (1) |
|
|
377 | (2) |
|
Atopic Eczema-Atopic Dermatitis |
|
|
379 | (1) |
|
|
379 | (1) |
|
|
380 | (3) |
|
|
381 | (1) |
|
|
382 | (1) |
|
Immunotherapeutic Modification of Atopic Allergy |
|
|
383 | (4) |
|
|
384 | (1) |
|
|
385 | (1) |
|
|
385 | (1) |
|
|
385 | (1) |
|
|
386 | (1) |
|
|
386 | (1) |
|
Pharmacologic Control of Atopic Reactions |
|
|
387 | (4) |
|
|
388 | (1) |
|
|
388 | (1) |
|
The Autonomic Nervous System |
|
|
389 | (1) |
|
Autoantibodies of β-Adrenergic Receptors |
|
|
389 | (2) |
|
|
391 | (3) |
|
|
391 | (1) |
|
|
392 | (1) |
|
|
392 | (1) |
|
|
393 | (1) |
|
Allergic Bronchopulmonary Aspergillosis |
|
|
393 | (1) |
|
|
394 | (1) |
|
|
395 | (6) |
|
T-Cell-Mediated Cytotoxicity |
|
|
401 | (30) |
|
|
401 | (1) |
|
TCTL, TDTH, and Natural Killer Cells |
|
|
401 | (3) |
|
|
402 | (1) |
|
|
402 | (2) |
|
Induction of T-Cell Immunity |
|
|
404 | (1) |
|
TCTL-Cell Reactions in Vitro |
|
|
405 | (1) |
|
TCTL-Cell Reactions In Vivo |
|
|
406 | (21) |
|
|
406 | (3) |
|
|
409 | (8) |
|
Pregnancy: a Tolerated Graft |
|
|
417 | (2) |
|
|
419 | (1) |
|
|
420 | (1) |
|
|
420 | (3) |
|
|
423 | (1) |
|
|
423 | (4) |
|
|
427 | (1) |
|
|
427 | (4) |
|
Delayed-Type Hypersensivitiy |
|
|
431 | (21) |
|
TDTH-Cell Reactions: Delayed-Type Hypersensitivity |
|
|
431 | (1) |
|
TDTH-Cell Activation and Superantigens |
|
|
432 | (2) |
|
Delayed-Type Hypersensitivity Skin Reaction |
|
|
434 | (2) |
|
Cutaneous Basophil Hypersensitivity |
|
|
436 | (1) |
|
|
436 | (1) |
|
Delayed-Type Hypersensitivity and Infection |
|
|
437 | (2) |
|
|
437 | (2) |
|
TDTH-Cell-Mediated Autoimmune Disease |
|
|
439 | (4) |
|
Experimental Allergic Encephalomyelitis |
|
|
439 | (2) |
|
Human Encephalomyelitis and Multiple Sclerosis |
|
|
441 | (1) |
|
Experimental Allergic Neuritis |
|
|
442 | (1) |
|
Experimental Allergic Sympathetic Neuritis |
|
|
442 | (1) |
|
|
443 | (4) |
|
Animal Models of Viral Encephalitis |
|
|
443 | (2) |
|
Viral Encephalitides of Humans |
|
|
445 | (2) |
|
TCTL and TDTH Cells, Tuberculosis, and Leprosy |
|
|
447 | (1) |
|
|
448 | (1) |
|
|
448 | (4) |
|
|
452 | (26) |
|
|
452 | (3) |
|
|
455 | (18) |
|
|
455 | (11) |
|
Granulomatous Responses to Known Antigens |
|
|
466 | (2) |
|
Diseases of Unknown Etiology |
|
|
468 | (4) |
|
Immune Deficiency Diseases |
|
|
472 | (1) |
|
Protective Functions of Granulomatous Reactions |
|
|
472 | (1) |
|
|
473 | (1) |
|
|
473 | (5) |
|
Interplay of Inflammatory and Immunopathologic Mechanisms, Immune Defense, and Evasion of Immune Defense Mechanisms during Infection |
|
|
478 | (32) |
|
|
478 | (1) |
|
|
478 | (3) |
|
Interaction of Immune and Nonimmune Inflammation |
|
|
481 | (1) |
|
Immune-Specific Protection against Infection |
|
|
481 | (7) |
|
|
482 | (2) |
|
|
484 | (1) |
|
|
484 | (1) |
|
|
485 | (1) |
|
Helminth (Worm) Infections |
|
|
486 | (1) |
|
|
487 | (1) |
|
|
487 | (1) |
|
Summary of the Role of Immune Mechanisms in Protection against Infections |
|
|
487 | (1) |
|
Interaction of Immune Mechanisms in Some Infectious Diseases |
|
|
488 | (4) |
|
|
488 | (2) |
|
Strongyloides Hyperinfection |
|
|
490 | (2) |
|
Evasion of Immune Defense Mechanisms |
|
|
492 | (13) |
|
Echinococcosis: Protected Niche |
|
|
494 | (1) |
|
HIV: Intracellular Location and Immunosuppression |
|
|
494 | (1) |
|
Chlamydia trachomatis: Endosomes |
|
|
494 | (1) |
|
Streptococus pneumoniae: Resistance to Phagocytosis |
|
|
494 | (1) |
|
Mycobacterium tuberculosis: FasL Expression |
|
|
495 | (1) |
|
Schistosomiasis: Protective Niche, Masking of Surface Antigens, Complement Misdirection, and Th1-versus-Th2 Response |
|
|
495 | (1) |
|
Vaccinia Virus: Control of Complement Activation |
|
|
496 | (1) |
|
Trypanosomiasis: Antigenic Modulation |
|
|
496 | (1) |
|
Measles: Immunosuppression |
|
|
497 | (1) |
|
Influenza Virus: Stearic Hindrance |
|
|
498 | (1) |
|
Herpes Simplex Virus: Intracellular Location, Bipolar Bridging, and Complement Inhibition |
|
|
498 | (1) |
|
Malaria: FasL Expression, Antibody-Mediated Infection, and Peptide Inhibition of Antigen Presentation |
|
|
499 | (1) |
|
Ascaris lumbricoides: Extracorporeal Location and MHC-Restricted Recognition |
|
|
499 | (1) |
|
Adenovirus: Downregulation of Class I MHC and Inhibition of Apoptosis |
|
|
500 | (1) |
|
Cytomegalovirus: Class I and II MHC Degradation and Molecular Decoys |
|
|
500 | (1) |
|
Leprosy and Syphilis: Immune Deviation |
|
|
501 | (1) |
|
Poxviruses: Effector Modulation and Soluble Receptors |
|
|
502 | (1) |
|
Epstein-Barr Virus: IL-10 |
|
|
502 | (1) |
|
Leishmaniasis: Complement-Mediated Endocytosis, Inhibition of Macrophage Killing, Modulation of T-Cell Immunity, and Immune Deviation |
|
|
503 | (2) |
|
|
505 | (2) |
|
|
507 | (3) |
|
Immune-Mediated Skin Diseases |
|
|
510 | (18) |
|
|
510 | (3) |
|
|
510 | (1) |
|
Functions of the Skin Immune System |
|
|
511 | (2) |
|
Antibody-Mediated Skin Diseases |
|
|
513 | (1) |
|
Inactivation or Activation |
|
|
513 | (2) |
|
|
513 | (2) |
|
Epidermolysis Bullosa Acquisita |
|
|
515 | (1) |
|
Cytotoxic or Cytolytic Reactions |
|
|
515 | (2) |
|
Dermatitis Herpetiformis and Gluten-Sensitive Enteropathy (Sprue, or Celiac Disease) |
|
|
516 | (1) |
|
|
516 | (1) |
|
|
516 | (1) |
|
|
517 | (1) |
|
|
517 | (1) |
|
|
517 | (1) |
|
|
517 | (1) |
|
|
518 | (1) |
|
|
518 | (1) |
|
Cutaneous Vasculitis in Infectious Diseases |
|
|
518 | (1) |
|
|
518 | (2) |
|
|
518 | (1) |
|
|
519 | (1) |
|
|
519 | (1) |
|
|
519 | (1) |
|
Hypocomplementemic Vasculitic Urticarial Syndrome |
|
|
520 | (1) |
|
|
520 | (1) |
|
|
520 | (3) |
|
|
520 | (2) |
|
Delayed-Type Hypersensitivity Reactions |
|
|
522 | (1) |
|
|
523 | (1) |
|
|
523 | (1) |
|
|
523 | (1) |
|
|
523 | (1) |
|
|
524 | (1) |
|
|
524 | (1) |
|
|
524 | (1) |
|
|
524 | (4) |
|
Immunoproliferative Diseases |
|
|
528 | (28) |
|
|
528 | (1) |
|
Maturation of Blood-Forming Cells and Leukemia |
|
|
529 | (1) |
|
Lymphoid Tissue Structure and Lymphoproliferative Disease |
|
|
529 | (1) |
|
Tissue Localization of Lymphoid Cells |
|
|
529 | (1) |
|
Nonmalignant Lymphoproliferation |
|
|
529 | (3) |
|
|
532 | (19) |
|
|
533 | (12) |
|
|
545 | (3) |
|
Angioimmunoblastic Lymphadenopathy |
|
|
548 | (1) |
|
|
549 | (2) |
|
Infections Associated with Lymphoproliferative Diseases |
|
|
551 | (1) |
|
|
551 | (1) |
|
|
552 | (4) |
|
Immunodeficiency Diseases |
|
|
556 | (34) |
|
Immune Deficiencies and Infections |
|
|
556 | (2) |
|
Immune Response of Immature Animals |
|
|
557 | (1) |
|
Hypogammaglobulinemia of Infancy |
|
|
557 | (1) |
|
Neonatal Wasting Syndrome (TORCH) |
|
|
558 | (1) |
|
Primary Immunodeficiencies |
|
|
558 | (15) |
|
Mouse Models of Primary Immunodeficiencies |
|
|
559 | (1) |
|
Severe Combined Immunodeficiencies |
|
|
559 | (4) |
|
T-Cell Activation Deficiencies |
|
|
563 | (2) |
|
|
565 | (1) |
|
Other T-Cell Deficiencies |
|
|
565 | (1) |
|
B-Cell Immunodeficiencies |
|
|
566 | (2) |
|
|
568 | (5) |
|
Secondary Immunodeficiencies |
|
|
573 | (4) |
|
|
573 | (1) |
|
|
574 | (2) |
|
Malcirculation of Lymphocytes |
|
|
576 | (1) |
|
|
576 | (1) |
|
|
576 | (1) |
|
|
577 | (1) |
|
Evaluation of Immunodeficiency |
|
|
578 | (1) |
|
|
579 | (7) |
|
|
579 | (1) |
|
Passive Cell-Mediated Antibody |
|
|
580 | (6) |
|
|
586 | (1) |
|
|
587 | (3) |
|
|
590 | (38) |
|
Human Immunodeficiency Virus |
|
|
590 | (8) |
|
AIDS-Related Retroviruses |
|
|
590 | (2) |
|
|
592 | (1) |
|
HIV Replication and Gene Expression |
|
|
593 | (1) |
|
The HIV Replicative Cycle |
|
|
594 | (3) |
|
|
597 | (1) |
|
|
598 | (23) |
|
|
598 | (1) |
|
|
599 | (1) |
|
Natural History of HIV Infection |
|
|
600 | (4) |
|
Cellular Dynamics of HIV Infection |
|
|
604 | (1) |
|
Immune Stimulation and Activation of AIDS |
|
|
604 | (2) |
|
Laboratory Diagnosis of HIV Infection |
|
|
606 | (2) |
|
Immune Dysfunction in AIDS |
|
|
608 | (1) |
|
Pathology and Clinical Staging |
|
|
609 | (2) |
|
|
611 | (4) |
|
|
615 | (1) |
|
Vaccination against HIV Infection |
|
|
616 | (5) |
|
|
621 | (2) |
|
|
623 | (5) |
|
|
628 | (57) |
|
History of Tumor Immunity |
|
|
628 | (1) |
|
Evidence for Tumor Immunity in Humans |
|
|
628 | (3) |
|
Carcinogenesis and Tumor Immunity |
|
|
631 | (1) |
|
|
632 | (6) |
|
|
632 | (2) |
|
The Immune Response of the Primary Tumor-Bearing Host and Concomitant Immunity |
|
|
634 | (1) |
|
Etiology and Immunogenicity of Tumors |
|
|
634 | (1) |
|
Virus-Induced Tumor Antigens |
|
|
635 | (2) |
|
|
637 | (1) |
|
Mechanisms of Tumor Cell Destruction by the Immune System |
|
|
638 | (4) |
|
In Vitro Assays of Tumor Immunity |
|
|
638 | (3) |
|
Antibody-Mediated Tumor Immunity |
|
|
641 | (1) |
|
|
641 | (1) |
|
|
642 | (5) |
|
|
642 | (1) |
|
Failure of Immunosurveillance |
|
|
643 | (4) |
|
Immunodiagnosis of Cancer |
|
|
647 | (15) |
|
|
650 | (1) |
|
|
651 | (1) |
|
|
651 | (1) |
|
|
652 | (1) |
|
|
653 | (2) |
|
Cell Surface Carbohydrates |
|
|
655 | (3) |
|
|
658 | (1) |
|
|
658 | (1) |
|
|
658 | (2) |
|
|
660 | (1) |
|
Immunoglobulin Gene Rearrangements |
|
|
660 | (1) |
|
|
661 | (1) |
|
|
661 | (1) |
|
|
662 | (14) |
|
|
662 | (1) |
|
|
662 | (3) |
|
Evaluation of Immunotherapy |
|
|
665 | (1) |
|
|
665 | (1) |
|
|
666 | (1) |
|
|
666 | (1) |
|
|
667 | (1) |
|
|
668 | (1) |
|
CMV and T-Killer Adoptive Immunotherapy |
|
|
669 | (1) |
|
|
669 | (1) |
|
|
670 | (1) |
|
|
670 | (1) |
|
|
670 | (2) |
|
|
672 | (1) |
|
|
672 | (1) |
|
Antigen-Targeted Adoptive Transfer Therapy |
|
|
673 | (1) |
|
|
673 | (3) |
|
|
676 | (1) |
|
|
676 | (9) |
Appendix 1 History of Immunopathology |
|
685 | (6) |
Appendix 2 Evolution of Immunity (Phylogeny) |
|
691 | (6) |
Appendix 3 Cluster-of-Differentiation Molecules |
|
697 | (20) |
Appendix 4 Cytokines |
|
717 | (4) |
Appendix 5 Clinical Immunology Tests |
|
721 | (6) |
Appendix 6 Tables of Lymphoproliferative Diseases |
|
727 | (4) |
Index |
|
731 | |